Literature DB >> 4005843

Biological and biophysical properties of the tumor-localizing component of hematoporphyrin derivative.

D Kessel, M L Cheng.   

Abstract

Reverse-phase chromatography, aqueous gel exclusion, and nonaqueous gel exclusion were assessed as procedures for preparative fractionation of the tumor-localizing product hematoporphyrin derivative. Porphyrin accumulation, fluorescence, and photodynamic cytotoxicity were monitored using the murine Sarcoma 180 tumor. Aqueous gel exclusion chromatography can provide a hematoporphyrin derivative fraction enriched in the tumor-localizing component. A further enrichment occurs when this procedure is carried out at 55 degrees C, but nonlocalizing porphyrins could not be eliminated. While providing a better separation, reverse-phase chromatography cannot provide a tumor-localizing fraction free from contaminating protoporphyrin. However, this and other contaminants can be eliminated from the tumor-localizing fraction via nonaqueous gel exclusion chromatography. This latter separation provides two tumor-localizing products: a fast-eluting fraction enriched in the major photosensitizing component(s); and a more complex slowly eluting fraction enriched in fluorescence localizers.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005843      PMCID: PMC4563995     

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  On the preparation and properties of dihematoporphyrin ether, the tumor-localizing component of HPD.

Authors:  D Kessel; M L Cheng
Journal:  Photochem Photobiol       Date:  1985-03       Impact factor: 3.421

2.  Properties of a new state of hematoporphyrin in dilute aqueous solution.

Authors:  F Ricchelli; L I Grossweiner
Journal:  Photochem Photobiol       Date:  1984-11       Impact factor: 3.421

Review 3.  Hematoporphyrin and HPD: photophysics, photochemistry and phototherapy.

Authors:  D Kessel
Journal:  Photochem Photobiol       Date:  1984-06       Impact factor: 3.421

4.  Photodynamic inactivation of R3230AC mammary carcinoma in vitro with hematoporphyrin derivative: effects of dose, time, and serum on uptake and phototoxicity.

Authors:  R Hilf; P B Leakey; S J Sollott; S L Gibson
Journal:  Photochem Photobiol       Date:  1983-06       Impact factor: 3.421

5.  Photoradiation therapy--clinical and drug advances.

Authors:  T J Dougherty; D G Boyle; K R Weishaupt; B A Henderson; W R Potter; D A Bellnier; K E Wityk
Journal:  Adv Exp Med Biol       Date:  1983       Impact factor: 2.622

6.  Tumor-localizing components of the porphyrin preparation hematoporphyrin derivative.

Authors:  D Kessel; T H Chou
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

7.  Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue.

Authors:  C J Gomer; T J Dougherty
Journal:  Cancer Res       Date:  1979-01       Impact factor: 12.701

8.  Uptake of the components of hematoporphyrin derivative by cells and tumours.

Authors:  J Moan; S Sommer
Journal:  Cancer Lett       Date:  1983-12       Impact factor: 8.679

9.  Equilibrium and kinetic studies of the aggregation of porphyrins in aqueous solution.

Authors:  S B Brown; M Shillcock; P Jones
Journal:  Biochem J       Date:  1976-02-01       Impact factor: 3.766

10.  In vivo biological activity of the components of haematoporphyrin derivative.

Authors:  M C Berenbaum; R Bonnett; P A Scourides
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

View more
  6 in total

1.  Adventures in photodynamic therapy: 1976-2008.

Authors:  David Kessel
Journal:  J Porphyr Phthalocyanines       Date:  2008-07-24       Impact factor: 1.811

2.  Photodynamic therapy for malignant tumours of the ampulla of Vater.

Authors:  A M Abulafi; J T Allardice; N S Williams; N van Someren; C P Swain; C Ainley
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

3.  Evaluation of tumour and tissue distribution of porphyrins for use in photodynamic therapy.

Authors:  K W Woodburn; S Stylli; J S Hill; A H Kaye; J A Reiss; D R Phillips
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

4.  Evaluation of porphyrin C analogues for photodynamic therapy of cerebral glioma.

Authors:  G Karagianis; J S Hill; S S Stylli; A H Kaye; N J Varadaxis; J A Reiss; D R Phillips
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

5.  Cell uptake, distribution and response to aluminium chloro sulphonated phthalocyanine, a potential anti-tumour photosensitizer.

Authors:  W S Chan; R Svensen; D Phillips; I R Hart
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

6.  Selective accumulation of hematoporphyrin derivative in glioma through proton-coupled folate transporter SLC46A1.

Authors:  Tomoya Takada; Masato Tamura; Tetsuya Yamamoto; Hirofumi Matsui; Akira Matsumura
Journal:  J Clin Biochem Nutr       Date:  2013-12-20       Impact factor: 3.114

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.